Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe

The rituximab biosimilar CT‐P10 is approved for the treatment of non‐Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT‐P10 and reference rituximab. However, real‐world data relating to treatment in patients with DLBCL with rituximab biosimilars are limited. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bishton, Mark J., Salles, Gilles, Golfier, Camille, Knauf, Wolfgang, Bocchia, Monica, Turner, Deborah, Slama, Borhane, Harchowal, Jatinder, Marshall, Scott, Bosi, Alberto, Lleonart, Juan José Bargay, Welslau, Manfred, Kim, SooKyoung, Lee, Young N., Zinzani, Pier L., Laribi, Kamel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928637/
https://www.ncbi.nlm.nih.gov/pubmed/36819165
http://dx.doi.org/10.1002/jha2.593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928637/
https://www.ncbi.nlm.nih.gov/pubmed/36819165
http://dx.doi.org/10.1002/jha2.593

Ejemplares similares